Glaukos GKOS recently announced positive data from a new 36-month follow-up analysis of its two Phase 3 pivotal clinical trials evaluating its latest approved product, iDose TR.

Analysts have set 12-month price targets for Glaukos, revealing an average target of $170.86, a high estimate of $200.00, and ...

Stifel lowered the firm’s price target on Glaukos (GKOS) to $140 from $175 and keeps a Buy rating on the shares. The firm surveyed 34 iDose ...

Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Glaukos (GKOS) to $165 from $180 and keeps an Overweight rating on the ...

Glaukos Corporation (NYSE ... devices, or services. iDose TR (travoprost intracameral implant) is a long duration prostaglandin analog approved for a single administration and indicated for ...

Glaukos Corporation's shares have dropped 21 ... Given the strong success of iDose TR over the past 12 months, management is fully aware that momentum must be built on getting surgeons up to ...

Learn more about whether Glaukos Corporation or LeMaitre Vascular, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today ...